Analyst consensus rating
Caris Life Sciences Analyst Rating: Buy
CAI is rated Buy by 12 analysts with a $27.00 target. As of 2026-08-31.
Direct answer
Caris Life Sciences's consensus rating is Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.00.
Forecast evidence checked August 31, 2026.
Get free Caris Life Sciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $25.63
- Average price target
- $27.00
- High price target
- $36.00
- Low price target
- $22.00
- Low target gap
- -14.2%
- Target upside
- +5.3%
- High target gap
- +40.5%
- Target range width
- 54.6%
- Consensus rating
- Buy
- Analysts
- 12
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Caris Life Sciences?
Caris Life Sciences has a verified Buy consensus. The same dataset has an average price target of $27.00.
How far are Caris Life Sciences's low and high targets from the recorded price?
The low target implies -14.2%, while the high target implies +40.5%.
How many analysts are included in Caris Life Sciences's consensus?
The verified consensus includes 12 analysts.
How is Caris Life Sciences's target upside or downside calculated?
The average target of $27.00 is divided by the recorded price of $25.63, then one is subtracted to produce +5.3%. This does not guarantee a future return.
When was Caris Life Sciences's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.